Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02089334
Title Dose-Finding, Safety and Efficacy Study of RX-0201 Plus Everolimus in Metastatic Renal Cell Cancer
Recruitment Terminated
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Rexahn Pharmaceuticals, Inc.
Indications

renal cell carcinoma

Therapies

Everolimus + RX-0201

Everolimus

Age Groups: adult
Covered Countries USA


No variant requirements are available.